Macroadenoma biochemical behavior in pediatric patients with Cushing’s disease differs from adult cases

Cushing’s disease in children is associated with similar biochemical measures whether the disease is due to macroadenomas or microadenomas, according to a presentation at the AACE 24th Annual Scientific & Clinical Congress.

This contrasts with the disease behavior in adults, in whom macrodenomas demonstrate less glucocorticoid suppression and adrenocorticotropic hormone (ACTH) response to laboratory tests than do microadenomas, according to researchers.

“Children with pituitary macroadenomas are more likely to have the classical response to Cushing’s disease functional testing as microadenomas,”Ricardo Correa, MD, a clinical and research endocrinology fellow at National Institutes of Health, told Endocrine Today.

Correa and colleagues conducted a retrospective review of patients with Cushing’s disease who were younger than 18 years when they were admitted to the NIH between 1997 and 2014. All Cushing’s diagnoses were confirmed by pathology.

Pituitary macroadenoma was identified in 13 patients (69% female) and microadenoma in 74 (58% female). The groups had similar mean age (14 years) and BMI (31.8 kg/m2 and 30.2 kg/m2 for macroadenoma and microadenoma, respectively). The macroadenoma group had a median (25% to 75%) 24-hour urine free cortisol of  263.60 mcg/24 hr (range 170.7-528) compared with 371.6 mcg/ 24 hr (range 244.2-625.3) in the microadenoma group (P = 0.47). Median 24-hr urinary 17-hydroxysteroid excretion in the macroadenoma group was 12.6 mg/24 hr (range 8.9-42.5) and 31.6 mg/24 hr (range 4.3-39.9) in the microadenoma group.

Mean morning serum cortisol was 38.9 ± 40.4 mcg/dL compared with  20.2 ± 15.8 mcg/dL in the macroademona and microadenoma groups, respectively (P = 0.16). Mean morning basal plasma ACTH was 106.3 ± 112.3 pg/mL compared with 49.9±44.3 pg/mL for the macroadenoma and microadenoma groups, respectively (P = 0.11), while ACTH responses to the ovine corticotropin-releasing hormone test revealed no statistically significant differences. Using the high dose dexamethasone suppression test, 58% (7/12) suppressed more than 69% in the macroadenoma group compared to 69% (44/64) in the microadenoma group (P = .51).

“Studies in adult patients have demonstrated that macroadenomas have less glucocorticoid suppressibility after the high-dose dexamethasone suppression test and attenuated ACTH response to CRH compared to pituitary microadenomas,” according to Correa. “However, the present study shows that this is not true in children; although patients with macroadenomas had a tendency for higher baseline serum ACTH and cortisol levels, their responses to dynamic testing were similar to those with microadenomas.”

Reference:

Correa R, et al. Abstract #803. Presented at: AACE 24th Annual Scientific & Clinical Congress; May 13-17, 2015; Nashville, Tenn.

Disclosure: The researchers report no relevant financial disclosures.

From http://www.healio.com/endocrinology/adrenal/news/online/%7Bb4fbf36f-ac88-4eff-9278-90f0a8d1aec2%7D/macroadenoma-biochemical-behavior-in-pediatric-patients-with-cushings-disease-differs-from-adult-cases?sc_trk=internalsearch

Mortality in cured Cushing’s disease

In patients diagnosed with Cushing’s disease, mortality is high compared to the general population However, it is not yet known if this mortality remains high even after initial therapy.

Therefore van Haalen et al., performed a systematic review and meta-analysis of follow-up studies in patients cured from Cushing’s disease after initial treatment. They found that mortality remained high in patients with Cushing’s disease even after initial biochemical cure remission, suggesting that cure does not directly reverse the metabolic consequences of long-term overexposure to cortisol.

Read full article by van Haalan et al., titled ‘Mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis’, European Journal of Endocrinology 172, R143-R149.

DOI: 10.1530/EJE-14-0556

From http://www.ese-hormones.org/news/article.aspx?articleid=9083

The Voices of Cushing’s Disease, Part III: Finding Strength in Numbers

Part III of The Voices of Cushing’s Disease video series discusses the importance of support for people living with Cushing’s disease.

 

The Voices of Cushing’s Disease, Part II: A Day in the Life

Part II of The Voices of Cushing’s Disease video series discusses the daily challenges of people living with Cushing’s disease and highlights the importance of disease management.

For more information, please visit http://www.aboutcushings.com outside of the US or http://www.cushingsdisease.com in the U.S.

Pituitary Tumor Roundtable – Part One: A Focus on Diagnosis

Novartis is committed to supporting the pituitary community and continues to address the evolving needs of patients and caregivers.

In this video, a multidisciplinary panel discusses the diagnosis of acromegaly and Cushing’s disease.

For more information, visit: http://www.AboutAcromegaly.com and http://www.AboutCushings.com.